Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage ...
Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Recursion Pharmaceuticals saw its stock price increase by 12% over the past week. This movement could be associated with several recent developments. The company announced a significant follow-on ...
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...
I'm about 98% done building an app for parsing a certain network vendor's XML dumps, and need some help with group objects I know I should have used etree, but minidom seemed too straight forward to ...
Sept 3 (Reuters) - Nvidia-backed Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback